International access
Cancer treatment in Malaysia
A regional referral destination with many private facilities serving international patients.
Orientation information, not an access guarantee
Facilities
Public-reference profiles
This list does not state partnership, quality, schedule, price, or international patient acceptance.
- Not verified
Subang Jaya Medical Centre
Subang Jaya
Public registry
Recorded clinical trials
Available clinical trial counts are calculated from public registries and may change at any time. Counts shown on the page follow the most recent registry data imported.
NCT06452277Phase 3Immunotherapy
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Lung Cancer | biomarker: HER2 | Immunotherapy, Chemotherapy
United States, Argentina, Australia +33279 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker HER2, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT06452277Not verified
NCT07468071Phase 1 / Phase 2Targeted therapy
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
Lung Cancer | biomarker: KRAS | Targeted therapy
Belgium, Canada, China +720 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker KRAS, the treatment category is Targeted therapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Active, not recruiting
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT07468071Not verified
NCT07185997Phase 3Targeted therapy
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Lung Cancer | biomarker: EGFR | Targeted therapy
United States, Australia, Canada +14139 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker EGFR, the treatment category is Targeted therapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT07185997Not verified
NCT05920356Phase 3Combination regimen
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Lung Cancer | biomarker: KRAS, PD-L1 | Immunotherapy, Targeted therapy, Chemotherapy
United States, Argentina, Australia +35421 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker KRAS, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT05920356Not verified
What needs confirmation
- • Visa, stay permit, and entry requirements for medical care must be checked through official government and embassy channels. TanyaKanker does not guarantee acceptance.
- • Service availability, written estimate, inclusions and exclusions.
- • Follow-up plan after returning to Indonesia.
Ask about access in Malaysia
Organise the case and questions without promises of acceptance, price, or treatment outcome.
After submission, a human navigator reviews your request and contacts you through your chosen channel. The WhatsApp message already includes this page context, so you do not need to explain from the beginning.
Clinical data is not requested in the form and is not sent to analytics. Do not send medical reports through WhatsApp or email; use the secure upload page. We do not promise eligibility or any treatment outcome.